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Using the Payoff Time in Decision-Analytic
Models: A Case Study for Using Statins
in Primary Prevention
Alexander Thompson, MSc, Bruce Guthrie, PhD, Katherine Payne, PhD
Background. The payoff time represents an estimate of
when the benefits of an intervention outweigh the costs. It
is particularly useful for benefit-harm decision making for
interventions that have deferred benefits but upfront
harms. The aim of this study was to expand the applica-
tion of the payoff time and provide an example of its use
within a decision-analytic model. Methods. Three clini-
cally relevant patient vignettes based on varying levels of
estimated 10-year cardiovascular risk (10%, 15%, 20%)
were developed. An existing state-transition Markov model
taking a health service perspective and a life-time horizon
was adapted to include 3 levels of direct treatment disuti-
lity (DTD) associated with ongoing statin use: 0.005, 0.01,
and 0.015. For each vignette and DTD we calculated a
range of outputs including the payoff time inclusive and
exclusive of healthcare costs. Results. For a 10% 10-year
cardiovascular risk (vignette 1) with low-levels of DTD
(0.005), the payoff time was 8.5 years when costs were
excluded and 16 years when costs were included. As the
baseline risk of cardiovascular increased, the payoff time
shortened. For a 15% cardiovascular risk (vignette 2) and
for a low-level of DTD, the payoff time was 5.5 years and
9.5 years, respectively. For a 20% cardiovascular risk
(vignette 3), the payoff time was 4.2 and 7.2 years, respec-
tively. For higher levels of DTDs for each vignette, the pay-
off time lengthened, and in some instances the interven-
tion never paid off, leading to an expected net harm for
patients. Conclusions. This study has shown how the pay-
off time can be readily applied to an existing decision-
analytic model and be used to complement existing mea-
sures to guide healthcare decision making. Key words:
payoff time; direct treatment disutility; cost-effectiveness;
cardiovascular; decision-analytic modelling. (Med Decis
Making 2017;37:759–769)
C linicians are increasingly encouraged to con-sider the evidence on benefits and harms along-
side a temporal dimension when making treatment
decisions for older people and/or those with multi-
morbidities whose life expectancy may be limited.1–3
The rationale underpinning this suggestion is clear.
People with limited life expectancy may never
accrue the benefits from interventions with deferred
effects, making the use of such interventions point-
less in some groups of patients. Where there are
upfront harms associated with an intervention, there
is also the potential for net harm if individuals do
not live long enough to accrue sufficient benefit.
The ‘‘payoff time’’ is a potentially useful concept
to consider the temporal dimension in benefit-harm
decision making. It is defined as the ‘‘minimum
time until the cumulative incremental benefits that
are attributable to a guideline exceed its cumulative
incremental harms.’’5(p2) Where the life expectancy
of an individual is less than an intervention’s
expected payoff time, then the rational decision
Received 26 July 2016 from Manchester Centre for Health
Economics, University of Manchester, Manchester, UK (AT, KP); and
Population Health Sciences Division, University of Dundee, UK (BG).
Financial support for this study was provided National Institute for
Health Research Health Services and Delivery Research Programme
(Project No. 11/2003/27). The funding agreement ensured the
authors’ independence in designing the study, interpreting the data,
and writing and publishing the report. The views and opinions
expressed therein are those of the authors and do not necessarily
reflect those of the HS&DR Programme, NIHR, NHS, or Department
of Health. The authors have no conflicts of interest to declare.
Revision accepted for publication 6 February 2017.
Address correspondence to Alexander Thompson, MSc, Manchester
Centre for Health Economics, 4th floor, Jean McFarlane Building, The
University of Manchester, Oxford Road, Manchester, M13 9PL, UK;
telephone: +44 161-306-7685; fax: +44 161-275-5205; e-mail: alex-
ander.thompson@manchester.ac.uk.
 The Author(s) 2017
Reprints and permission:
http://www.sagepub.com/journalsPermissions.nav
DOI: 10.1177/0272989X17700846
ORIGINAL ARTICLE
MEDICAL DECISION MAKING/OCTOBER 2017 759
would be not to implement the intervention.
Decision making using the payoff time approach
therefore requires the calculation of a number of
inputs: the expected benefits and harms over time;
the point in time where the benefits exceed the
harms; and the life expectancy of the patient.
Heuristics for calculating these inputs have been
proposed to make the payoff time approach a practi-
cal way to improve shared decision making.5–7
There is also potential to integrate the payoff time
within cost-effectiveness analysis,8,9 as McCabe and
others10 have demonstrated providing information
to reimbursement agencies on how long it takes for
benefits to outweigh the financial costs of imple-
menting healthcare programs in a given patient pop-
ulation.10,11 This paper focuses on developing the
payoff time concept within a shared decision-making
framework, although its secondary analysis also
takes a more traditional health economic perspective
by including costs into the analysis.
Current examples in the literature of the payoff
time concept have included the examination of inter-
ventions with up-front risk of harm and deferred
benefits such as in vascular procedures (e.g., carotid
endarterectomy for risk reduction),7 the use of inten-
sive glucose control in type 2 diabetes, and screening
for colon cancer.6 These published applications of
the payoff time concept were all estimated using rel-
atively simple mathematical calculations based on
probabilities and expected outcomes. None of the
examples included the costs of treatment as a deci-
sion input.4–7 However, the concept has clear poten-
tial to be applied in the kind of decision-analytic
framework used to assimilate evidence on the out-
comes and costs of alternative healthcare interven-
tions in health technology assessment.12
The aim of this paper is to provide an example of
how the payoff time can be (1) integrated within a
decision-analytic model-based economic evaluation;
(2) useful for decision making for benefit-risk
Figure 1 (a) The QALY concept (top). (b) Cumulative incremental QALYs over time (bottom). pt represents the payoff time when costs
are not included; QALYs are quality-adjusted life-years; T represents the full time horizon; IBQ represents the maximum incremental
net benefit at time T measured in QALYs; Iq represents the maximum investment size measured in QALYs; It represents the time the
maximum investment size occurs.
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judgements in a shared decision-making framework
where patients are undergoing a long-term preven-
tive intervention associated with some small treat-
ment disutility that may vary from person to person.
THEORY OF THE PAYOFF TIME
The Conceptual Framework
Figure 1a illustrates the QALY (quality-adjusted
life-year) concept. The QALY combines length of
life and health status or health-related quality of life
(HRQoL) into a single metric and allows for both
health gains and harms to be measured on the same
scale. For a given health state hð Þ, health status is
typically quantified using preference-weighted
scores that can be represented by a time-independent
utility function (u hð Þ). Assuming there are 2 options
for the treatment of a patient, then as seen in Figure
1a, u h1ð Þ represents the flow of health status result-
ing from intervention 1 over time including death
and u h0ð Þ represents the flow of health status result-
ing from a ‘‘no-treatment’’ option including death
over time. In the illustrative example in Figure 1a,
the intervention causes an initial fall in health status
when compared with no-treatment (‘‘harm’’ due to
treatment). The initial harm can also be considered
an investment with an associated size measured in
QALYs (Iq) and within a defined time period Itð Þ.
The overall incremental benefit (IB) of the interven-
tion versus no-treatment measured in QALYs (IBQ)
can be characterized as the difference in the health
status between the 2 treatment options summed over
discrete units of time (t) over the whole time horizon
(T) using Equation 1:
IBQ5
XT
t
u h1tð Þ  u h0tð Þ: ð1Þ
Figure 1b shows how the QALY underpins the
simplest calculation of the payoff time for an indi-
vidual. The concept of IB can also be used to gener-
ate a profile of cumulative QALYs over the full time
horizon. The example in Figure 1b shows how the
intervention produces an initial harm (or requires
an initial investment) but leads to an overall QALY
gain IBQ
 
occurring at time Tð Þ. The payoff time
ptð Þ is the point shown on Figure 1b where the
incremental benefit measured in QALYs becomes
positive by crossing the x-axis. Similarly, in Figure
1a, ptð Þ occurs where the initial harm (shaded) is
recouped by health gains (dark shaded). In Equation
1, the payoff time is also equivalent to IBq,t50
(where t\T) following IBq,t1\0.
In practice, the plot of health status and life
expectancy over time for an individual receiving
the intervention can never be observed simultane-
ously with the counterfactual of ‘‘no-intervention.’’
Randomized controlled trials are the gold standard
method to provide a causal estimate of the out-
comes that are generated by the 2 scenarios (inter-
vention and no-intervention) by averaging the
effects for each patient sample randomly allocated
to each group. Consequently, it is only feasible to
estimate expected (population-level), and not indi-
vidual, values of IB and payoff time. For simplicity,
this assumption is made throughout this paper.
The Inclusion of Costs
An extension to calculating a QALY-based bene-
fit-risk payoff time is to include healthcare costs
within the calculation10,11 using the incremental
net benefit framework.8 In this framework, both
costs and QALYs are converted onto the same scale
using a cost-effectiveness threshold (l). Equation 2
shows the incremental net health benefit (INHB):
INHB5
XT
t
u h1tð Þ  u h0tð Þð Þ  (cost(h1t)
cost(h0t))  1=lð Þ; ð2Þ
where costs h1tð Þ represents the healthcare costs for
the intervention and relevant health states over dis-
crete units of time, and costs h0tð Þ represents the
healthcare costs for the no-intervention option and
relevant health states over discrete units of time.
The incorporation of l in the equation transforms
the monetarily expressed costs into an equivalent
QALY value by making reference to a threshold (l),
representing the opportunity cost of spending
within the health service or the willingness to pay
for an additional QALY.13 Typical values for l used
by the National Institute for Health and Care
Excellence (NICE) are in the range of £20,000–
£30,000 per QALY gained.14 A positive INHB
implies that the intervention is cost-effective versus
the no-treatment option at the selected cost-effec-
tiveness threshold (l). An alternative formulation
for Equation 2 would be to transform the measure of
benefit into costs, again using the threshold (l), to
generate an incremental net monetary benefit.
To calculate a payoff time, Equation 2 can be
plotted over time.10,11 In this analysis the ‘‘payoff
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time’’ represents the point in time at which the
intervention becomes cost-effective for a given
explicitly defined cost-effectiveness threshold (l)
compared with a relevant comparator: the time
point where benefits outweigh the initial resources
required for investment as well as those expected
downstream. When allocating scarce healthcare
resources, McCabe and others highlight how deci-
sion makers are likely to value a formal framework
calculating the payoff time (as well as its uncer-
tainty) in INHB10 and how it can be potentially be
used to share risk between payers and providers
and smooth investment decisions over time.11
Direct Treatment Disutilities
Previous studies have focused on clinical situa-
tions where there is a large, but transient, upfront
harm due to a surgical or other one-off procedure,
with deferred benefits subsequently accruing.7 The
initial upfront harm is then integrated with the
downstream treatment benefits in order to calculate
an expected payoff time. For preventive treatments
that are taken long term, such as antihypertensives
or statins, a one-off harm (or disutility) is not usu-
ally meaningful, but the concept of direct treatment
disutility (DTD) becomes relevant. DTDs have previ-
ously been defined as representing an individual’s
strength of preference not to undergo regular treat-
ment separate from an any potential adverse effect
resulting from treatment.15 Disutility beyond that
caused by specific treatment-related adverse effects
could occur because of the inconvenience associ-
ated with treatment, such as obtaining prescriptions
and collecting medicines, taking them daily, and
having follow-up tests or appointments. Disutility
may also arise because patients find treatment an
unpalatable prospect in its own right. A previous
review has highlighted an emerging literature
which seeks to elicit DTDs and has described the
consequences of including DTD values within cost-
effectiveness modeling for long-term preventive
interventions.15 Within such a context, the interpre-
tation of the payoff time for a preventive interven-
tion is the point in time where the benefits out-
weigh the initial and ongoing DTDs associated with
treatment. Equation 1 with the inclusion of direct
treatment disutility becomes Equation 3:
XT
t
u h1t  treatð Þ  u h0tð Þ; ð3Þ
where u treatð Þ represents the ongoing time-invar-
iant direct treatment disutility. There is no com-
mensurate disutility associated with no-treatment.
The Modeling Framework
A number of types of decision-analytic models
are available for use in cost-effectiveness analysis
(CEA).16 For model developers, selecting the appro-
priate model requires an explicit process involving
a number of stakeholders in order to make clear the
simplifying assumptions of the model-type and its
appropriateness to capture the relevant treatment
and disease processes.17
Decision trees lack an internal time component
so are not a useful model type if a payoff time is
required. By comparison, state-transition Markov
models have time within their structure in the form
of model cycles. Consequently, Markov models
require only a trivial extension to the modeling
framework to calculate payoff times. To calculate a
payoff time for a long-term preventive intervention,
such as a statin for primary prevention, the initial
step is to check whether any harms were included,
or planned to be included, in the model-based CEA.
Harm is defined as the reduction in HRQoL, or an
increase in risk for the new intervention versus the
old, within any time period. Step 2 involves includ-
ing a relevant, literature-sourced DTD for the inter-
vention arm with no DTD in the no-treatment arm.
Step 3 calculates an expected value for the cumula-
tive QALYs and/or net benefit for each model cycle
for the whole cohort for all the alternative treatment
strategies. Step 4 involves calculating the incremen-
tal outputs by subtracting the cumulative outputs
for the alternative strategies. The calculation of the
payoff time can be found indirectly by identifying
the point in time at which the cumulative incre-
mental QALYs become positive. This value can be
readily visualized on a plot of cumulative incre-
mental QALYs against time from model start. If the
observed payoff time occurs between model cycles,
then a linear interpolated time can be estimated by
assuming a common trend between the time points.
The payoff time can be calculated inclusive of
healthcare resources with only a trivial extension to
the previous steps.
For an individual level approach, such as the use
of a discrete event simulation (DES) model,18,19 the
calculation of the payoff time is less straightforward
but it is feasible to calculate individualized payoff
times by modeling individual patients in different
THOMPSON AND OTHERS
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counterfactuals and by comparing outcomes. For
those developing a new model, the payoff time cal-
culation should be a core part of the design, and a
number of attributes tracking the timing of events
would be needed to allow estimation for the payoff
time. A substantial advantage of the use of a DES
model is the ability to capture patient-level hetero-
geneity rather than having to prespecify a number
of homogenous cohorts in state-transition Markov
models. However, it is unlikely that payoff times
can be calculated retrospectively for existing DES
models without significant redesign.
EXAMPLE OF THE PAYOFF TIME: PRIMARY
PREVENTIVE INTERVENTION USING STATINS
The Model
A published state-transition Markov model previ-
ously developed by the National Centre for Clinical
Guidelines (NCGC) and used to inform a NICE
clinical guideline was used as the framework to
illustrate an application of the methods described
above.20,21 The model was designed to assess the
relative cost-effectiveness of statin therapy for pri-
mary and secondary prevention of cardiovascular
disease. Here we focus only on primary prevention.
The 2014 NICE guidelines on lipid modification rec-
ommend offering statin treatment for primary pre-
vention to all people with an estimated 10-year risk
of cardiovascular disease of 10%.21 The equivalent
US guideline recommends initiating statins in peo-
ple aged up to 75 years at a 10-year risk threshold of
7.5% and to consider initiation if 10-year risk is 5%–
7.5%.22 Almost all UK residents will cross the 10%
threshold at some point in their late 50s or 60s, but
the recommendation ignores that some older patients
will have reduced life expectancy from other causes,
which makes consideration of payoff time relevant.
Figure 2 shows the schematic for the Markov
model structure that included 15 health states,
including all-cause mortality and CVD-mortality.
Treatment options included in this analysis were
Figure 2 Schematic of economic model. Every health state links to all-cause mortality and CVD-mortality. *Adapted from the National
Clinical Guideline Centre (NCGC) cost-effectiveness model on lipid modification.20
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no-treatment and high-intensity statin treatment.
The model followed the NICE reference case,14
assumed an NHS perspective, took a life-time time-
horizon, discounted costs and QALYs at 3.5%, and
could be run for different age cohorts (age: 40 years,
50 years, 60 years, 70 years) and levels of baseline
risk of cardiovascular disease. The original analysis
used to inform the clinical guideline showed high-
intensity statin treatment to be highly cost-effective
at a threshold of £30,000 per QALY. No patient
harm was included in the existing model; that is,
statin use was assumed to have no increased risk of
adverse outcomes, and DTDs were assumed be zero.
Analysis
Patient vignettes were generated (see Box 1) to
provide clinically relevant scenarios to illustrate
how to quantify the impact of the payoff time. Three
patient vignettes were created with input from clini-
cians (3 general practitioners and 4 specialists with
experience of managing cardiovascular disease). The
patient vignettes were focused on the management of
male patients built around scenarios defined by esti-
mated 10-year cardiovascular risk scores of 10%,
15%, and 20% (as calculated by QRISK2,23 the tool
currently recommended by NICE to estimate cardio-
vascular risk21).
The published state-transition Markov model
was adapted to allow calculation of cumulative
incremental QALYs and net benefit for each 1-year
model cycle. We added 3 levels of DTDs (0.005,
0.01, 0.15) in the model, which were informed by a
review of the current literature.15 The DTDs were
applied annually to the whole cohort within the
model and did not decrease over time. Payoff time
was defined by the interpolated model cycle in
which the net benefit became positive. In total, the
following were calculated when costs were not
included in the analysis: absolute QALYs and
equivalent healthy days; payoff time (years); time to
peak investment in QALYs (years); investment size
(QALYs). The following were also calculated when
costs were included in the analysis and a threshold
of £20,000 per QALY gained was assumed: overall
net benefit (£); payoff time (years).
RESULTS
Table 1 summarizes the calculated values result-
ing from the adapted model.
Patient Vignette 1
Vignette 1 reflects a patient who is a 60-year-old
man whose cardiovascular risk was largely driven
by age and gender. The results in Table 1 show that
high-intensity statin treatment was a cost-effective
option when there was no DTD, with a positive net
benefit of £2865 for a cost-effectiveness threshold of
£20,000. As there was no harm or DTD included in
the model, the intervention paid off immediately
when measured in QALYs, and the incremental
cumulative QALY gain was estimated to be 0.20
QALYs per patient equal to approximately 73 days
at full health. Figure 3 shows the QALY profile for
Vignette 1. Of note is that even low DTD was associ-
ated with payoff times measured in years, and the
expected absolute QALY gain was sensitive to the
presence of DTD. For example, a DTD of 0.005 was
Box 1 Three Patient Vignettes for Differing
QRISK2-Estimated Cardiovascular Risk Scores
Vignette Description
Vignette 1
A 60-year-old man who has no history of type 2
diabetes. He is a nonsmoker, with systolic blood
pressure of 150 mm Hg. He is 178 cm and weighs 75
kg with a body mass index (BMI) of 23.7. His fasting
lipid panel reveals a total/HDL ratio of 3.3. He
would like to discuss statin therapy but is worried
about the potential for side effects.
His 10-year cardiovascular risk estimated by QRISK2
is 10%.
Vignette 2
A 60-year-old man who has no history of type 2
diabetes. He is a light smoker, with systolic blood
pressure of 140 mm Hg. He is 178 cm and weighs 80
kg with a BMI of 25.2. His fasting lipid panel reveals
a total/HDL ratio of 4.2. He would like to discuss
statin therapy.
His 10-year cardiovascular risk estimated by QRISK2
is 15%.
Vignette 3
A 70-year-old man who has no history of type 2
diabetes. He is a nonsmoker, with systolic blood
pressure of 140 mm Hg. He is 178 cm and weighs 85
kg with a BMI of 26.8. His fasting lipid panel reveals
a total/HDL ratio of 4.1. He would like to discuss
statin therapy.
His 10-year cardiovascular risk estimated by QRISK2
is 20%.
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associated with a payoff of 8.5 years when mea-
sured in QALYs with a peak investment (or harm)
occurring at 6.5 years for a QALY loss of 0.01.
When the size of the DTD was set at 0.015 or above,
then statin treatment never pays off and there is a
QALY loss of 0.03 QALYs over the whole period.
When accounting for costs and a threshold of
£20,000 per QALY, the payoff time was 7.5 years
with no DTD included in the model. This payoff
time rose to 16 years with a DTD of 0.005, and the
intervention never paid off for DTDs of 0.01 and
0.015.
Patient Vignette 2
Vignette 2 reflects a patient who is a 60-year-old
man whose 10-year cardiovascular risk of 15% is
driven by age, gender, smoking, and lipid profile.
The results in Table 1 show that high-intensity sta-
tin treatment was a cost-effective option when there
is no direct treatment disutility, with a positive net
benefit of £4936 for a cost-effectiveness threshold of
£20,000. The intervention paid off immediately
when measured in QALYs. Likewise, the absolute
QALY gain was estimated to be 0.29 QALYs per
patient equal to approximately 106 days at full
health. Figure 3 shows the QALY profile for
Vignette 2. Of note is that even low DTD is
associated with payoff times measured in years
(although as expected, payoff times are shorter and
absolute QALY gains are greater when baseline risk
of cardiovascular disease increases), and the
expected absolute QALY gain is sensitive to the
presence of DTD. When the size of the DTD was set
at 0.015, then statin treatment only pays off after
19.7 years.
When accounting for costs and a threshold of
£20,000 per QALY, the payoff time was 4.4 years
with no DTD included in the model. This payoff
time rose to 9.5 years for a DTD of 0.005, 15.7 years
for a DTD of 0.01, and 27.3 years for a DTD of 0.015.
Patient Vignette 3
Vignette 3 reflects a patient who is a 70-year-old
man whose 10-year cardiovascular risk of 20% is
driven by age, gender, and lipid profile. The results
in Table 1 show that high-intensity statin treatment
is a cost-effective option when there is no direct
treatment disutility, with a positive net benefit of
£3847 for a cost-effectiveness threshold of £20,000.
The intervention paid off immediately when mea-
sured in QALYs, with an absolute QALY gain esti-
mated to be 0.22 QALYs per patient equal to
approximately 80 days at full health. Figure 3 illus-
trates that even low DTD was associated with payoff
Table 1 Key Results
Direct Treatment
Disutility (Harm)
Equivalent No. of
Full Health
Days Tradeda
Incremental
QALY
QALYs
Payoff
Time (Years)
Peak
Investment
Size (QALYs)
Peak
Investment
(Years)
Incremental Net
Monetary
Benefit (£)b
Incremental Net
Monetary Benefit
(Payoff Time)b
Patient vignette 1
Zero 0 0.2 Immediatec 0 N/A £2865 7.5
0.005 55 0.12 8.5 –0.01 6.5 £1307 16
0.01 110 0.05 18.9 –0.036 9.5 –£249 Neverd
0.015 164 –0.03 Neverc –0.077 13.5 –£1806 Neverd
Patient vignette 2
Zero 0 0.29 Immediatec 0 N/A £4936 4.4
0.005 55 0.21 5.5 –0.006 4.5 £3400 9.5
0.01 110 0.14 11.7 –0.025 6.5 £1864 15.7
0.015 164 0.06 19.7 –0.054 9.5 £328 27.3
Patient vignette 3
Zero 0 0.22 Immediatec 0 0.5 £3847 3.3
0.005 55 0.17 4.2 –0.005 2.5 £2687 7.2
0.01 110 0.11 8.9 –0.019 4.5 £1527 12.2
0.015 164 0.05 15.2 –0.041 6.5 £367 20.6
a. Over the course of treatment with statins over 30 years.
b. Measured in years, assuming a cost-effectiveness threshold of £20,000 per QALY.
c. For zero DTD, treatment immediately pays off with no harm.
d. For very large DTD treatment never pays off because harm always exceeds benefit.
USING THE PAYOFF TIME IN DECISION-ANALYTIC MODELS
ORIGINAL ARTICLE 765
times measured in years (although again, as
expected, payoff times were lower and absolute
QALY gains were greater when baseline risk of car-
diovascular disease increased), and the expected
absolute QALY gain was sensitive to the presence
of DTD. For example, a DTD of 0.005 was associated
with a payoff of 4.2 years rising to 15.2 years for a
DTD of 0.015.
When accounting for costs and a threshold of
£20,000 per QALY, the payoff time was 3.3 years
with no DTD included in the model. This payoff
time rises to 7.2 years for a DTD of 0.005, 12.2 years
for a DTD of 0.01, and 20.6 years for a DTD of 0.015.
DISCUSSION
This study has applied the 2 emerging concepts
of payoff time and DTD to an existing decision-ana-
lytic model designed to assess the relative cost-
effectiveness of statins for the primary prevention of
cardiovascular disease. It illustrated how evidence
regarding the temporal dimension of treatment deci-
sions can be generated retrospectively using exist-
ing economic evidence. The calculation of payoff
time together with visual presentation of the infor-
mation provides a potentially useful tool to comple-
ment existing cost-effectiveness results and aid
decision making when choosing between interven-
tions with different payoff times.
We provided 2 estimates of payoff time. The first
focused on the balance between benefits and harms,
which is more useful for individualized patient-
level decisions for treatments judged cost-effective
by technology appraisers and guideline developers.
In these models, the existing model-based CEA
assumed no upfront harm or DTD and estimated
immediate (zero) payoff times, but incorporating
DTD led to substantial payoff times including fail-
ure to ever payoff in some scenarios. The second
estimates we generated were inclusive of healthcare
costs and are likely to be of particular interest for
those assessing public health interventions or diag-
nostic technologies that could have significant
upfront costs but deferred patient benefits or down-
stream cost savings. Where costs were included in
the model, the payoff times varied from 3.3 to 7.5
years assuming no DTD. Substantial payoff times
were estimated in the presence of DTD including
scenarios in which the intervention failed to ever
payoff. The development of tools to calculate the
return on investment for public health interventions
for NICE24 or budget impact and costing tools sug-
gests a demand for alternative forms of evidence by
commissioners and policy makers. However, these
tools do not currently account for upfront harms or
DTD, and an explicit calculation of the payoff time
has yet to be used. Our study showed how a payoff
time inclusive of healthcare costs can be generated
from an existing decision-analytic model.
Figure 3 QALY profiles for 3 patient vignettes with 4 levels of
direct treatment disutility (harm) from treatment.
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The American Geriatrics Association (AGA) out-
lined key principles for the care of older people
with multimorbidity in 2012, including that ‘‘time
to benefit’’ and expected absolute benefit should
inform clinical decision making. AGA recom-
mended that interventions in this population
should ideally be prioritized based on evidence of
net benefit occurring within an individual’s
expected lifetime. However, robust evidence on a
temporal dimension is not currently available for
decision makers. For example, current clinical
guidelines such as those produced by NICE gener-
ally do not provide explicit information on the tem-
poral dimensions of benefit, with at most trial-dura-
tion being stated as a surrogate for the treatment
time required to receive a benefit from an interven-
tion. Decision making is further constrained by a
clinical evidence base that has typically adopted a
simplistic statistical approach to handling ‘‘compet-
ing risks.’’ For example, in survival analysis asses-
sing a disease-specific endpoint, a common naı¨ve
approach is to treat the occurrence of a competing
event (e.g., death not because of the disease) as
independently censored. Consequently, those sub-
jects who do experience the competing event are
handled as if they are still at risk of the disease
endpoint in the future, leading to the potential over-
estimation of this risk and an overestimation of the
subsequent benefits and cost-effectiveness of treat-
ments.25–27 Where the risk of the competing event is
particularly high, such as death in older patients
who are multimorbid,28 a naı¨ve approach can lead
to unnecessary and potentially harmful treatment.25
Further work is needed to ensure that appropriate
statistical methods are used within trials to estimate
benefit and in the development of competing risk-
adjusted risk-prediction algorithms to stratify treat-
ment decisions. The impact of properly accounting
for competing risk on payoff times is also a clear
research interest.
The methods developed in this paper begin to
allow a temporal dimension to be incorporated into
benefit-risk decision making and allow for absolute
measures of benefit to be calculated. Future studies
could generate estimates of the payoff time for other
interventions likely to be taken alongside statins,
such as antihypertensives. The majority of people
with any chronic condition are multimorbid29 and
so are likely to be prescribed multiple interventions
each with differing payoff times. Providing decision
makers with a range of competing payoff times
allows for prioritization between interventions,
particularly preventive interventions where benefits
accrue further into the future.
Limitations
There are some potential limitations with our
application of the payoff time approach for current
decision making. We do not conduct probabilistic
sensitivity analysis to generate ranges for our payoff
estimates as others have done so for reimbursement
decisions.10,11 Instead we used 1-way sensitivity
analyses for differing levels of DTDs and baseline
risks. Given that the DTD value for an individual
and the impact these values have on payoff time are
of primary interest, this form of 1-way sensitivity
analysis was deemed to be most straightforward to
apply to our research problem. Ideally, all the
uncertainty, including uncertainty around DTD,
would be incorporated within the analysis simulta-
neously as is the case in probabilistic sensitivity
analysis.
A methodological limitation is whether there are
quantifiable estimates of DTD. There is increasing
evidence that patients negatively value taking long-
term preventive medications and that if properly
accounted for in decision-analytic models, these
DTD values could have important consequences for
cost-effectiveness.21 Future research generating
robust empirical estimates for DTD using well-
designed stated preference studies in appropriate
samples of the patient population and members of
the public is required. These studies need to pro-
vide evidence on the level of heterogeneity of DTD
values between patients, providing the scope to
potentially use individualized or group-level DTD
values within individual-level models such as a
DES. It is also uncertain how best to incorporate
DTD into the utility values for the patient cohort
being run through a Markov model. In this study, a
constant harm (DTD value) was used and the utility
decrement was taken from the total utility for the
relevant model cycle. Research is needed to explore
the validity of these assumptions that DTD is con-
stant over time and that simple subtraction of the
disutility value is an appropriate approach.
It is not currently clear what the best approach is
to discount benefits for the payoff time in the IB
framework and benefits and costs for a payoff time
in the INHB framework. In this paper both benefits
and costs were discounted at 3.5% but there is the
potential for ‘‘double discounting’’ on the benefit
side if the method of eliciting DTD values has
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already incorporated individuals’ time-preference
(e.g., within a time tradeoff exercise) and DTD val-
ues are then further discounted in the model-based
analysis. For the calculation of a payoff time within
the INHB framework, McCabe and colleagues10 con-
ducted sensitivity analyses for differing discount
rates for benefits (1.5%) and costs (3.5%) and found
the impact on the expected payoff time to be small
but the impact on the uncertainty of the estimate to
be substantial. Future models calculating the payoff
time for primary preventive interventions with an
associated DTD could explore the impact of time-
preference on the results when more is known as to
how patients discount DTDs over long periods.
A similar conceptual problem relates to the risk
aversion of the decision maker. In this paper we
have assumed individuals within a shared decision-
making framework would be happy to make deci-
sions based on expected outcomes. In short, they
are risk-neutral like a societal decision maker allo-
cating resources over time. Consequently, any posi-
tive expected payoff time that falls within an indi-
vidual’s lifetime would be a rational treatment
choice. If, instead, individual decision makers are
risk averse, as is more likely to be the case, then this
may not hold. Future work could explore these con-
ceptual implications further alongside the calcula-
tion of payoff times for other potentially ‘‘compet-
ing’’ interventions for cardiovascular disease, such
as antihypertensives, in order to inform potential
prioritization decisions.
CONCLUSION
Evidence on a temporal dimension to net benefit
has been argued to be essential to prioritize and
select interventions, particularly for patients with
multimorbidity. We have shown how current deci-
sion-analytic models can readily be modified to
estimate the payoff time and that payoff time is a
potentially useful tool to aid decision making in the
context of developing clinical guidelines. Further
research is required to generate more estimates of
payoff time for a range of different interventions so
prioritization can occur. Further empirical research
is also needed to generate estimates of DTDs, how
to best include DTD within decision-analytic mod-
els, and how to present uncertainty around esti-
mates of payoff time. Ideally, DES models will form
the basis for future payoff time calculations allow-
ing for individualized estimates to be made and
used in decision making.
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